Noninvasive positive pressure ventilation in acute respiratory failure: Does it improve outcomes?

ALEJANDRO C. ARROLIGA, MD
Head, Section of Critical Care Medicine, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic

ABSTRACT
Studies have shown that noninvasive positive pressure ventilation (NPPV) is well tolerated and safe, and that it improves oxygenation in some patients with acute respiratory failure. By obviating the need for endotracheal intubation in certain conditions, it results in fewer complications, shorter hospital stays, and consequently, lower mortality rates and costs of care.

Why insert an endotracheal tube when a mask may do? For many patients with acute respiratory failure, noninvasive positive pressure ventilation (NPPV), in which a mask or mouthpiece is used, can give the benefits of standard endotracheal ventilation without subjecting the patient to intubation, with its attendant complications.

Interest in NPPV has grown since 1987, when several reports found that it relieved symptoms and improved gas exchange in patients with chronic respiratory failure. Since then, it has been successfully used in many patients with acute respiratory failure as well, and its use has increased dramatically in the last 5 years. At the Cleveland Clinic, the number of patient-days on NPPV increased to approximately 1,600 in the year 2000, nearly four times as many as in 1995.

Because NPPV avoids some of the complications of intubation (pneumonia, sinusitis, and trauma to the airway), NPPV patients incur shorter hospital stays, lower mortality rates, and lower healthcare costs. Another advantage is that it is more comfortable for the patient, who retains the ability to speak, swallow, and protect the upper airway.

This discussion focuses on use of NPPV in the intensive care unit and in the care of patients with acute respiratory failure due to severe exacerbations of chronic obstructive pulmonary disease (COPD), cardiogenic pulmonary edema, and acute hypoxemic nonhypercapnic respiratory failure, including severe pneumonia or acute respiratory distress syndrome (ARDS).

Types of NPPV
There are three commonly used ways of delivering NPPV:

- Continuous positive airway pressure (CPAP), in which the machine delivers air at a constant positive pressure during inspiration and expiration
- Volume-cycled, flow-limited, in which the machine delivers a set tidal volume each time the patient begins to take a breath
- Pressure-limited, which in turn can be of three types:
  - Pressure support, in which the machine delivers air at a set pressure during inspiration every time the patient starts to take a breath
  - Pressure control, in which the machine automatically delivers a set number of breaths per minute at a set pressure
- Bilevel positive airway pressure (BiPAP), in which the machine delivers different pressures during inspiration and expiration.

What type is best?
Pressure support and BiPAP are the most common types of NPPV used today, but stud-
ies to gauge which is best have been inconclusive.4 Because all the types appear to be similarly efficient, the choice should be made on the basis of local expertise and tailored to the cause and severity of the patient’s respiratory failure.4 The settings should be adjusted to provide the lowest inspiratory pressures or volume to make it as comfortable as possible for the patient while maintaining adequate oxygenation.

What type of mask?
NPPV is given through a full-face mask, a nasal mask, nasal “pillows,” or a mouthpiece. There has been some debate about which type of interface (ie, mask or mouthpiece) is most effective. There is no significant difference between types of masks.4 Ultimately, the best type of mask is the one with which the respiratory therapist and the patient feel most comfortable; several masks should be available for the patient to try. It is crucial that the mask be tight enough to avoid leakage but not so tight that the patient becomes agitated or the nasal bridge becomes ulcerated. Mouthpieces are more often used in patients with chronic respiratory failure, such as those with amyotrophic lateral sclerosis.

WHERE SHOULD NPPV BE GIVEN?
Ideally, NPPV should be started in an intensive care unit, but it can be started in other types of nursing units, provided they have good monitoring capacity. Any patient whose dyspnea does not improve or who experiences deterioration of mental status or hemodynamic derangement should be transported to an intensive care unit. Patients on NPPV need to be monitored carefully because those who do not improve within a short time of starting therapy are at high risk for cardiac complications such as arrhythmias and even cardiac arrest during intubation.

CAUTIONS, COMPLICATIONS
Not all patients are suitable candidates for NPPV. The patient must be alert and have a patent upper airway for ventilation and secretion removal. NPPV should be stopped or not used at all in patients with cardiac or respiratory arrest, severe encephalopathy, gastrointestinal bleeding, hemodynamic instability (ie, a drop in systolic blood pressure to below 90 mm Hg), unstable arrhythmia, abnormalities of the face, trauma or deformity, agitation that requires sedation, upper airway obstructions, inability to clear secretions, or a high risk of aspiration.4 In addition, edentulous patients or those with beards are likely to have large mouth leaks that may hinder administration of ventilation.5 Complications of NPPV include nasal bridge ulceration, nasal congestion, eye irritation, gastric distention, and aspiration.6 Gastric distention can be alleviated by using a nasogastric tube. Aspiration can be prevented by using NPPV only in patients who are awake and alert.

Efficacy of NPPV
NPPV appears to be most valuable in patients with exacerbations of COPD, although some success has been achieved in patients with cardiogenic pulmonary edema. Results in patients with acute hypoxemic nonhypercapnic respiratory failure have not been as encouraging.

Use of NPPV in COPD
Prospective randomized trials have demonstrated that 50% to 70% of patients who have severe exacerbations of COPD and who receive NPPV can avoid being intubated.7 Furthermore, the reduction in the need for intubation results in a reduction in the mortality rate. In addition, NPPV translates into shorter hospital stays and decreased costs of care.8 Survival is higher than without ventilation. Recently, Plant et al9 conducted a randomized controlled study in 236 patients with exacerbations of COPD to compare outcomes of NPPV (BiPAP) with those of standard therapy (which included oxygen by face mask or nasal cannula, prednisolone, bronchodilators, and antibiotics). Eighteen (15.3%) of the 118 patients receiving NPPV ultimately required intubation, compared with 32 (27%) of the 118 patients receiving standard therapy (P =
Moreover, fewer patients died who received NPPV: 12 (10%) vs 24 (20%) \( (P = 0.05). \)

Keenan et al\(^8\) conducted a meta-analysis and calculated the odds ratio of hospital mortality at 0.22 \( (95\% \text{ confidence interval } 0.10–0.66) \) for patients with severe exacerbations of COPD receiving NPPV compared with standard therapy. They also calculated that $3,244 (Canadian) would be saved per patient admission if NPPV were used instead of standard therapy.

**Response can be assessed in the first hour.** It is important to predict which patients are likely to respond to NPPV. In general, those who do best have normal mental status and are alert and able to accept the face mask.

Antón et al\(^10\) examined the records from 49 patients who received NPPV (BiPAP in spontaneous mode) to treat 59 episodes of acute respiratory failure. NPPV was successful (ie, the patient avoided being intubated) in 46 (77%) of the episodes. Using logistic regression analysis, the investigators found several factors that predicted success with NPPV:

- Higher level of consciousness on admission
- Lower FEV\(_1\) on admission
- Significant improvements in pH, PaCO\(_2\) and level of consciousness after 1 hour of NPPV. In patients in whom NPPV succeeded, the pH rose from a mean of 7.27 to 7.34, and the PaCO\(_2\) decreased from 81 to 68 mm Hg. In contrast, these measures did not change in patients in whom NPPV failed.

**Staffing time only slightly increased.** The time required for a nurse or respiratory therapist to spend with patients receiving NPPV is not significantly greater than that required for standard therapy. Plant et al\(^9\) estimated that in the first 8 hours of treatment, nurses and respiratory therapists spent about 24 more minutes with patients receiving NPPV.

**Survival may be higher than with invasive ventilation.** A study by Vitacca et al\(^11\) suggested that COPD patients who receive NPPV have a lower mortality rate than patients treated with invasive mechanical ventilation: 20% vs 26% in the intensive care unit, 23% vs 48% at 3 months, and 30% vs 63% at 1 year. These findings must be interpreted with caution because the study was retrospective and it was not clear whether the patients who received NPPV were less ill or whether patients remained on NPPV following hospital discharge.

**NPPV in cardiogenic pulmonary edema**

NPPV has had somewhat less encouraging results in patients with cardiogenic pulmonary edema: it does not result in significantly improved outcomes, but it does improve oxygenation faster and reduce the need for intubation. At least two randomized controlled trials\(^12,13\) showed that CPAP improved vital signs and oxygenation and reduced the need for intubation. However, one study\(^14\) raised some concern when it showed that patients who received CPAP experienced more myocardial infarctions than those treated with pressure support (71% vs 31%).

Masip et al\(^15\) in a recent prospective controlled randomized trial, compared the need for intubation and recovery time with NPPV vs conventional oxygen therapy. In the first half hour of treatment, patients receiving pressure support ventilation had better oxygenation; however, there was no significant difference in oxygenation between the two groups at 4 hours. Duration of hospital stay and the mortality rate were similar in both groups. However, six (33%) of the patients in the control group required intubation, compared with only one (5%) of the patients receiving NPPV. Patients who required intubation after receiving NPPV tended to have more radiographic evidence of cardiogenic pulmonary edema, a higher previous New York Heart Association score, and a higher PaCO\(_2\) (53 vs 44 mm Hg).

**NPPV in acute hypoxemic nonhypercapnic respiratory failure**

NPPV has been of limited use in the treatment of patients with acute hypoxemic nonhypercapnic respiratory failure, who in general do not have a history of COPD, are very hypoxic, and have bilateral infiltrates.\(^4\)

There has been some controversy about the indications for NPPV in these patients. Wysocki et al\(^16\) in a study of patients with
acute hypoxemic nonhypercapnic respiratory failure (most had pneumonia or cardiogenic pulmonary edema) found no improvement in patients treated noninvasively over those treated by conventional methods. However, they found that the rates of intubation and mortality were less and the length of hospital stay was shorter in patients with a higher PaCO₂ who received NPPV than in those with a low PaCO₂. Although the study was too small to yield clinically useful results, it did suggest that patients with a higher PaCO₂ may derive the most benefit from NPPV.

Confalonieri et al. in a multicenter prospective randomized trial, compared the efficacy of pressure support vs standard therapy in patients with severe community-acquired pneumonia who were in respiratory failure. NPPV was found to decrease the need for intubation and the length of stay in an intensive care unit.

Antonelli et al. performed a similar study, comparing the use of pressure support vs standard therapy. They found that the noninvasive method improved oxygenation and was as effective as conventional therapy in improving the ratio of PaO₂ to FiO₂. The ratio in the patients receiving noninvasive therapy was 116 and improved to 230; in patients receiving invasive therapy, 124 and 211. The rates of pneumonia and sinusitis were decreased in the group treated with NPPV.

In another multicenter prospective randomized trial, Delclaux et al compared the use of CPAP with use of oxygen alone. They found that at 1 hour patients treated with CPAP had better oxygenation, less dyspnea, decreased respiratory rate, and some improvement in pH. However, the differences between the two groups were no longer evident after an hour. In addition, there were no differences between the two groups in intubation requirements, length of stay in an intensive care unit, or mortality rate. Diverse events were more common with CPAP than with the use of oxygen alone, occurring in 14 (23%) of the CPAP group vs 5 (8%) of the oxygen group (P = .03). Four patients on CPAP experienced cardiac arrest vs 0 in the oxygen group.

**REFERENCES**


**ADDRESS:** Alejandro C. Arroliga, MD, Medical Intensive Care Unit, G62, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail arrolia@ccf.org.